Piper Jaffray analyst Sean Wieland kept his Overweight rating and $30 price target on Evolent Health, saying the ruling by a federal judge in Kentucky to vacate the approval for Medicaid work requirement waiver secures continued coverage and mitigates the risk for the company in that state. The analyst notes that further regulatory changes are now expected to boost Evolent’s value proposition and boost demand for its services.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.